PS2-35: Variation in Capture of Chemotherapy Data: Preliminary Findings From the CRN Economic Rx Burden Pilot Study

Background: A number of high-cost chemotherapy agents, including targeted biologic and genetic therapies, have been introduced to the U.S. in recent years. Much of the literature on use and costs of these new agents has been derived from clinical trials and Medicare/SEER-based studies. To date, few studies have been published describing diffusion and costs of new cancer therapies within or across health plan populations